The approval covers Limosilactobacillus fermentum CECT5716 LC40 (formerly Lactobacillus fermentum) and Loigolactobacillus coryniformis CECT5711 K8 (formerly Lactobacillus coryniformis).
L. fermentum CECT5716 LC40 was isolated from breast milk that has been clinically proven to provide a high level of protection in infants in cases of respiratory infections, said the company in a press release, while L. coryniformis CECT5711 K8, is a strain that reportedly boosts the immune system in adults and senior population.
The approval was welcomed by José María Roset, CEO of Biosearch Life. “For us it is great news that ANVISA has approved commercialization of our two strains in Brazil, a market with high potential for the company and from which we can access new clients seeking to provide probiotic solutions to consumers,” he said.
According to Business Wire, Brazil's probiotics market is estimated to be valued at 1,495,345 million dollars and is estimated to grow by 7.01% (CAGR) to reach a market size of 2,245,408 million dollars by 2025.